TABLE 2

Analysis of the different treatments

Treatment parameteraValue for the parametercP value
Total patient population (n = 77)Conventional-dose group (n = 36)Low-dose group (n = 41)
Duration from PCP onset to treatment (days)6.1 ± 5.26.3 ± 4.35.9 ± 5.90.26
TMP-SMX treatment
    Correction dose (mg/kg TMP)14.0 ± 4.117.5 ± 1.910.8 ± 2.8<0.001
    Duration of TMP-SMX therapy (days)16.9 ± 6.615.7 ± 6.118.1 ± 6.80.06
    Occurrence of adverse eventsb22 (28.6)15 (41.7)7 (17.1)0.02
    Dose reductiond15 (19.5)8 (22.2)7 (17.1)0.57
    Withdrawal or change to second-line regimend10 (13.0)7 (19.4)3 (7.3)0.22
Second-line regimen
    Pentamidine6 (7.8)5 (13.9)1 (2.4)0.06
    Atovaquone1 (1.3)0 (0)1 (2.4)0.35
ICU admission23 (29.9)9 (25.0)14 (34.1)0.38
Mechanical ventilation25 (32.5)11 (30.6)14 (34.1)0.74
Adjunctive corticosteroid therapy55 (71.4)26 (72.2)29 (70.7)0.89
  • a CTCAE, Common Terminology Criteria for Adverse Events; ICU, intensive care unit; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.

  • b CTCAE grade of ≥3.

  • c Unless noted otherwise, values are the number (percent) of patients. Other values are presented as means ± standard deviations.

  • d Dose reduction and withdrawal or change to second-line regimen were due to the occurrence of adverse events.